澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NEURIZON THERAPEUTICS LTD

0.076

-0.002-2.56%

成交量：33.82萬

成交額：2.57萬

市值：5,960.04萬

市盈率：-4.32

高：0.080

開：0.076

低：0.073

收：0.078

52周最高：0.165

52周最低：0.053

股本：7.84億

流通股本：3.51億

量比：0.30

換手率：0.10%

股息：- -

股息率：- -

每股收益(TTM):-0.018

每股收益(LYR):-0.018

淨資產收益率：-137.94%

總資產收益率：-45.31%

市淨率：4.68

市盈率(LYR):-4.32

資料載入中...

總覽公司新聞公告

Neurizon Therapeutics任命Chris Bremer為新任首席執行官

海利ALS平台試驗方案I完成入組 - Nuz-001頂線結果加速至2027年第二季度

BUZZ-澳大利亞Neurizon Therapeutics公司因與美國企業達成交易股價大漲

Neurizon Therapeutics獲倫理批准開展Nuz-001口服液體制劑一期研究

Neurizon Therapeutics Ltd 獲倫理批准，啓動Nuz-001口服液製劑一期研究

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/NUZ.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.076,"timestamp":1789107120000,"preClose":0.078,"halted":0,"volume":338216,"delay":0,"changeRate":-0.025641025641025664,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":784215600,"eps":-0.0176,"marketStatus":"休市中","change":-0.002,"latestTime":"09-11 16:12:00 AEST","open":0.076,"high":0.08,"low":0.073,"amount":25700,"amplitude":0.089744,"askPrice":0.078,"askSize":18821,"bidPrice":0.074,"bidSize":10500,"shortable":3,"etf":0,"ttmEps":-0.0176,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.078,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":0.30408397279174776,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NUZ.AU","preClose":0.078,"auctionPrice":0.076,"auctionVolume":23809,"auction":3,"marketStatus":"盘后竞价","timestamp":1789106402670}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-45.31%","roe":"-137.94%","lyrEps":-0.0176,"volumeRatio":0.30408397279174776,"shares":784215600,"dividePrice":0,"high":0.08,"amplitude":0.089744,"preClose":0.078,"low":0.073,"week52Low":0.053,"pbRate":"4.68","psRate":"3.39","week52High":0.165,"institutionHeld":0,"latestPrice":0.076,"committee":-0.28379,"eps":-0.0176,"divideRate":0,"volume":338216,"delay":0,"ttmEps":-0.0176,"open":0.076,"prevYearClose":0.085,"prevWeekClose":0.056,"prevMonthClose":0.056,"prevQuarterClose":0.06,"fiveDayClose":0.056,"twentyDayClose":0.062,"sixtyDayClose":0.062,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1173015776","title":"Neurizon Therapeutics任命Chris Bremer為新任首席執行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1173015776","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173015776?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 09:42","pubTimestamp":1788745358,"startTime":"0","endTime":"0","summary":"9月7日（路透社）——Neurizon Therapeutics Ltd宣布重大人事变动。该公司正式任命Chris Bremer为首席执行官，此项任命自2026年10月1日起正式生效。这一战略性人事调整标志着公司进入新的发展阶段。\n值得关注的是，Neurizon Therapeutics Limited作为一家在澳大利亚交易所上市的制药企业（股票代码：NUZ.AX），此次高层管理团队的更迭备受市场瞩目。新任CEO的加入将为公司带来怎样的战略变革与发展机遇，业界正拭目以待。\n关于Neurizon Therapeutics的更多后续动态，市场将持续关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164737610","title":"海利ALS平台試驗方案I完成入組 - Nuz-001頂線結果加速至2027年第二季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1164737610","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164737610?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 11:50","pubTimestamp":1784260213,"startTime":"0","endTime":"0","summary":"海利肌萎缩侧索硬化症（ALS）平台试验方案I的患者招募工作已全部完成。这一关键里程碑的达成，使得针对试验药物Nuz-001的顶线结果数据发布时间得以提前。根据最新计划，该项重要数据的公布时间现已被加速至2027年第二季度。此举标志着针对这一难治性神经退行性疾病的新药研发进程取得了又一阶段性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644479795","title":"BUZZ-澳大利亞Neurizon Therapeutics公司因與美國企業達成交易股價大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2644479795","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644479795?lang=zh_tw&edition=fundamental","pubTime":"2026-06-17 11:38","pubTimestamp":1781667529,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL4T42P08R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1941712348.USD","BK7096","LU1941712264.USD","NUZ.AU","BK4561","BK4007","ELAN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175076007","title":"Neurizon Therapeutics獲倫理批准開展Nuz-001口服液體制劑一期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1175076007","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175076007?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 09:59","pubTimestamp":1778637575,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics Ltd宣布，其Nuz-001口服液体制剂的一期临床研究已获得伦理批准。这一进展标志着该药物在开发流程中向前迈出了关键一步。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152075001","title":"Neurizon Therapeutics Ltd 獲倫理批准，啓動Nuz-001口服液製劑一期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1152075001","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152075001?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 07:21","pubTimestamp":1778628073,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics Ltd宣布，其候选药物Nuz-001的口服液制剂已获得伦理委员会批准，即将开展第一期临床研究。这一进展标志着该药物在开发道路上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}